Poolbeg Pharma (POLB) RNS Announcements

Add to Alert list
Date Time Source Announcement
24 Mar 2022 07:00 AM
RNS
AI deal signed with CytoReason
09 Mar 2022 07:00 AM
RNS
Notice of AGM
03 Mar 2022 07:00 AM
RNS
Final Results
28 Feb 2022 07:00 AM
RNS
Notice of Results
24 Feb 2022 07:00 AM
RNS
Artificial Intelligence deal with OneThree Biotech
31 Jan 2022 07:00 AM
RNS
Confirmation of vaccine platform licence execution
17 Jan 2022 07:00 AM
RNS
Exclusive license of RNA-based immunotherapy asset
16 Dec 2021 07:00 AM
RNS
Poolbeg to develop oral vaccine delivery platform
06 Dec 2021 07:00 AM
RNS
Poolbeg signs option for new vaccine candidate
25 Nov 2021 07:00 AM
RNS
Scientific Advisory Board Appointment
18 Nov 2021 07:00 AM
RNS
Update on POLB 001 Clinical Development
14 Oct 2021 09:05 AM
RNS
Second Price Monitoring Extn
14 Oct 2021 09:00 AM
RNS
Price Monitoring Extension
14 Oct 2021 07:00 AM
RNS
PredictViral Patent Update
07 Oct 2021 07:00 AM
RNS
RNA sequencing ahead of AI analysis programme
13 Sep 2021 07:00 AM
RNS
September and October Investor conferences
07 Sep 2021 07:00 AM
RNS
POLB001 US Patent Update
23 Aug 2021 09:06 AM
RNS
Second Price Monitoring Extn
23 Aug 2021 09:00 AM
RNS
Price Monitoring Extension
04 Aug 2021 11:30 AM
RNS
Holding(s) in Company
23 Jul 2021 01:26 PM
RNS
TR-1
19 Jul 2021 07:00 AM
RNS
Admission to AIM

Poolbeg Pharma is a biopharmaceutical company that develops and commercialises medicines for unmet medical needs, including rare and orphan diseases. Poolbeg Pharma focuses on developing medicines for areas of high unmet need, such as cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions like obesity. It is listed on the stock exchange under the ticker POLB.

POLB share price launched at 11p in 2021.

 

UK 100

Latest directors dealings